For IPO Boutique's "scale of 1 to 5" BUY rating on Pieris Pharmaceuticals, and our comprehensive analysis, click "Buy Market Research".
About Pieris Pharmaceuticals (adapted from Pieris Pharmaceuticals prospectus): Pieris is a clinical-stage biotechnology company that discovers and develops Anticalin protein-based drugs to target validated disease pathways in a unique and transformative way.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "PIRS" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
Used our Comprehensive Single Promo Advisory and want more?
